leisure time
This time last year, members of Congress were working around the clock to draft and pass the Inflation Reduction Act.
One of their goals was to address government spending on health care. But they specifically didn’t want to discourage research into rare disease treatments, so they exempted some of these so-called orphan drugs from the law.
advertisement
Unfortunately, the exemptions aren’t working as intended. Unless Congress acts, the IRA threatens to unravel one of America’s greatest medical and public policy success stories: the explosion of new treatments for patients living with rare diseases.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
What happened to the House vote on health price transparency?
Next article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： The cancer drug shortage isn’t new — and neither are the solutions
